TEAMSS (Transforming Expanded Access to Maximize Support and Study) seeks to advance clinical care and translational research by improving patient access to experimental therapies. This federated, national consortium for Expanded Access interventions is a partnership led by the University of Michigan with Duke University, University of Rochester and University of Texas Southwestern. Expanded Access provides an opportunity for patients who either lack therapeutic options or who are ineligible for clinical trials to potentially benefit from the clinical use of experimental drugs, biologics, and medical devices. By developing this national consortium, we will build a positive impact by, for the first time, creating a foundation for an integrated, nationwide approach to Expanded Access that can improve care for the most vulnerable patients.
Right now, in the right way: U. S. Food and Drug Administration’s expanded access program and patient rights - Holbein, M., Weatherwax, K., Gravelin, M., Hutchinson, R., & Mashour, G. (2018). Right now, in the right way: U. S. Food and Drug Administration’s expanded access program and patient rights. Journal of Clinical and Translational Science, 2(3), 115-117. doi:10.1017/cts.2018.318
The Critical Role of Medical Institutions in Expanding Access to Investigational Interventions - Spector‐Bagdady, Kayte, Weatherwax, Kevin J., Gravelin, Misty, and Shuman, Andrew G., “The Critical Role of Medical Institutions in Expanding Access to Investigational Interventions,” Hastings Center Report 49, no.2 ( 2019): 36– 39. doi:10.1002/hast.991